Missense mutations in p53 generate aberrant proteins with abrogated tumour suppressor functions that can also acquire oncogenic gain-of-function activities that promote malignant progression, invasion, metastasis and chemoresistance [1] [2] [3] [4] [5] . Mutant p53 (mutp53) proteins undergo massive constitutive stabilization specifically in tumours, which is the key requisite for the acquisition of gain-offunctions activities [6] [7] [8] . Although currently 11 million patients worldwide live with tumours expressing highly stabilized mutp53, it is unknown whether mutp53 is a therapeutic target in vivo. Here we use a novel mutp53 mouse model expressing an inactivatable R248Q hotspot mutation (floxQ) to show that tumours depend on sustained mutp53 expression. Upon tamoxifen-induced mutp53 ablation, allotransplanted and autochthonous tumours curb their growth, thus extending animal survival by 37%, and advanced tumours undergo apoptosis and tumour regression or stagnation. The HSP90/HDAC6 chaperone machinery, which is significantly upregulated in cancer compared with normal tissues, is a major determinant of mutp53 stabilization 9-12 . We show that long-term HSP90 inhibition significantly extends the survival of mutp53 Q/2 (R248Q allele 2 ) and H/H (R172H allele 3 ) mice by 59% and 48%, respectively, but not their corresponding p53 2/2 (also known as Trp53 2/2 ) littermates. This mutp53-dependent drug effect occurs in H/H mice treated with 17DMAG1SAHA and in H/H and Q/2 mice treated with the potent Hsp90 inhibitor ganetespib. Notably, drug activity correlates with induction of mutp53 degradation, tumour apoptosis and prevention of T-cell lymphomagenesis. These proof-of-principle data identify mutp53 as an actionable cancer-specific drug target.
Missense mutations in p53 generate aberrant proteins with abrogated tumour suppressor functions that can also acquire oncogenic gain-of-function activities that promote malignant progression, invasion, metastasis and chemoresistance [1] [2] [3] [4] [5] . Mutant p53 (mutp53) proteins undergo massive constitutive stabilization specifically in tumours, which is the key requisite for the acquisition of gain-offunctions activities [6] [7] [8] . Although currently 11 million patients worldwide live with tumours expressing highly stabilized mutp53, it is unknown whether mutp53 is a therapeutic target in vivo. Here we use a novel mutp53 mouse model expressing an inactivatable R248Q hotspot mutation (floxQ) to show that tumours depend on sustained mutp53 expression. Upon tamoxifen-induced mutp53 ablation, allotransplanted and autochthonous tumours curb their growth, thus extending animal survival by 37%, and advanced tumours undergo apoptosis and tumour regression or stagnation. The HSP90/HDAC6 chaperone machinery, which is significantly upregulated in cancer compared with normal tissues, is a major determinant of mutp53 stabilization [9] [10] [11] [12] . We show that long-term HSP90 inhibition significantly extends the survival of mutp53 Q/2 (R248Q allele 2 ) and H/H (R172H allele 3 ) mice by 59% and 48%, respectively, but not their corresponding p53 2/2 (also known as Trp53 2/2 ) littermates. This mutp53-dependent drug effect occurs in H/H mice treated with 17DMAG1SAHA and in H/H and Q/2 mice treated with the potent Hsp90 inhibitor ganetespib. Notably, drug activity correlates with induction of mutp53 degradation, tumour apoptosis and prevention of T-cell lymphomagenesis. These proof-of-principle data identify mutp53 as an actionable cancer-specific drug target.
Tumour-promoting gain-of-function activities of missense mutp53 alleles are demonstrated by knock-in mouse models [1] [2] [3] [4] [5] and in patients with Li-Fraumeni syndrome carrying germline TP53 missense mutations. Li-Fraumeni syndrome patients with TP53 missense mutations have earlier cancer onset than patients with loss of p53 expression 13, 14 . Strikingly, p53R248Q/1 Li-Fraumeni syndrome patients have higher tumour numbers and shorter tumour-free survival by 10.5 years than p53null/1 patients 2 . A key feature and prerequisite for gain-offunction is that mutp53 proteins undergo massive stabilization specifically in tumours [6] [7] [8] .
RNA-interference-mediated depletion of mutp53 produces marked cytotoxic effects in human cancer cells in culture and xenograft models 15 . Notably, mutp53 knockdown in orthotopic allografts of Kras G12D pancreatic murine cancer cells dramatically reduced their metastatic ability 16 . Together, this provides a strong rationale for testing mutp53-destabilizing cancer therapy in vivo. If confirmed, it might establish mutp53 as an important direct drug target in many cancer patients. To validate this rigorously, we generated conditional inactivatable p53 R248Q (floxQ) mice (Extended Data Fig. 1a -c) with a Rosa26CreERT2 (ERT2) knock-in allele, which mirror the constitutive R248Q (Q) mice 2 in tumour spectrum and survival (Extended Data Fig. 1d ). Tamoxifen/4-hydroxytamoxifen (4OHT) treatment activates CreERT2, causing deletion of the floxQ allele (with up to 90% efficiency) and cell death in primary T-cell lymphoma cultures, but not in various controls ( Fig. 1a and Extended Data Fig. 1e ). Likewise, transplantation assays into immunocompromised hosts (subcutaneous and tail vein allografts, prophylactic and therapeutic treatments) showed that floxQ deletion markedly inhibited tumour growth in vivo ( Fig. 1a-d and Extended Data Fig. 1f -h) and prolonged survival of recipients compared with controls ( Fig. 1b and Extended Data Fig. 1f ). These data strongly suggest tumour dependence on sustained high levels of mutp53.
Importantly, clinically advanced autochthonous tumours in floxQ/2 mice responded to mutp53 ablation with regression or stagnation ( Fig. 2a -c and Extended Data Fig. 2a ). Mechanistically, this was due to marked tumour apoptosis ( Fig. 2d ), but not cell cycle arrest (Extended Data Fig. 2b ). Notably, mutp53 ablation was also associated with strong suppression of lung metastasis, contrasting with large metastatic nodules in controls ( Fig. 2e ). Moreover, mutp53 ablation in floxQ/2 mice with early disease (10 weeks old) ( Fig. 2f ) extended median overall and T-lymphoma-specific survival by 37% from 128 to 175 days ( Fig. 2g and Extended Data Fig. 2c ). Notably, the improved overall survival of floxQ/2 mice, which normally have a significantly shorter lifespan than p53-null littermates 2 (Extended Data Fig. 1d ), now resembled that of p53-null mice (Extended Data Fig. 2d ), while their T-lymphoma-specific survival now extended beyond that of p53-null mice (Extended Data Fig. 2e ). This further indicates that tumours driven by mutp53 depend on stabilized mutp53. In support, at endpoint (death), most tumours of all types (17/23, 74%) from floxQ/2 mice that were tamoxifen-treated at 10 weeks were again composed of 100% mutp53-overexpressing cells ( Fig. 2h and Extended Data Fig. 2f ). This indicates strong selective pressure for the small minority of non-recombined mutp53positive cells outcompeting the majority of recombined cells. It is tempting to speculate that complete allele removal would have further improved survival. Thus, these data establish for the first time that continued expression of stabilized mutp53 is essential for tumour maintenance in vivo.
The HSP90 chaperone machinery is highly activated in cancers compared with normal tissues and renders them resistant to proteotoxic stress by supporting proper folding of conformationally aberrant oncoproteins including mutp53 (refs 17, 18) . Thus, cancer cells have a far smaller tolerance for HSP90 inhibition. We and others previously showed that HSP90 and its obligatory positive regulator, cytosolic HDAC6, are major determinants of mutp53 stabilization [9] [10] [11] [12] . Importantly, deletion of HSF1, the master transcriptional activator of the inducible heat-shock response including HSP90, dramatically suppresses oncogenicity in mutp53 H/1 mice, but has no effect in p53-null mice 19, 20 . These data clearly indicate that tumorigenicity of the H allele-but not of p53-null-strongly depends on Hsf1-mediated chaperone support, mainly HSP90. 17AAG and its hydrophilic derivative 17DMAG are ansamycin-derived highly specific first-generation Hsp90 inhibitors (Hsp90i) 17 . Likewise, histone deacetylase inhibitors, including FDA-approved SAHA, are promising anti-cancer drugs whose actions involve hyperacetylation of histone and select non-histone targets including HDAC6 substrate Hsp90, thus indirectly inhibiting Hsp90 (ref. 21) .
The cytotoxicity of 17AAG/SAHA in mutp53 cancer cells, despite being pleiotropic drugs, is largely due to the destabilization of mutp53 protein via Hsp90/HDAC6 inhibition 11, 12 . Moreover, owing to complementary drug targets, 17AAG/SAHA treatment caused synergistic cytotoxicity in human breast-cancer cells compared with monotherapy 11 . Likewise, 17AAG and SAHA synergized in T47D (p53L194F) xenografts in vivo (Extended Data Fig. 3 ). SAHA or 17AAG alone were effective in blocking tumour growth of parental MDA231 (p53R280K) cells, but lost their efficacy when excess ectopic mutp53 was present. Only the combination of both drugs overcame this block ( Fig. 3a) . To translate the genetic proof-of-principle results from floxQ/2 mice (Figs 1, 2) towards clinical application, we performed long-term treatments with 17DMAG1SAHA in mutp53R172H (H) mice 3 . Starting at 8 weeks when most H/H mice exhibited early intrathymic T-lymphoma ( Fig. 3b ), H/H and p53-null mice were treated lifelong with 17DMAG1SAHA versus vehicles. Strikingly, HSP90 inhibition benefited only H/H but not p53-null mice, extending their overall survival from a median 140 to 182 days (P , 0.001, Fig. 3c ). Moreover, drug treatment improved survival of H/H mice beyond that of p53-null mice ( Fig. 3d ). For T-lymphoma-specific survival, again only H/H but not p53-null controls benefited from 17DMAG1SAHA treatment (P , 0.001, Fig. 3e ). These data strongly support the idea that tumours expressing mutp53 depend on its presence and fundamentally differ in their oncogenic wiring from p53-null tumours. Moreover, the mechanism of action of these pleiotropic HSP90 inhibitors is mutp53-dependent.
Analysis of vehicle-and drug-treated thymic tissues at death for evidence of drug activity showed HSP90i activity (marked by transient induction of HSF1 target Hsp70 (ref. 22) ), but this did not significantly prevent tumours in p53-null mice (Fig. 3f ). In contrast, in H/H mice, when the drug worked (Hsp70 induced, mutp53 undetectable) it apparently prevented T-lymphoma formation in every case since we found only normal thymic tissues ( Fig. 3f , 'p53H/H normal thymus' mice 7-14, plus 12 mice analysed by autopsy). In contrast, in all six T-lymphomas that arose despite drug treatment, the drugs failed to inhibit HSP90 (Hsp70 not induced) ( Fig. 3f , 6/26 (23%) escapers). Mechanistically, NQO1 (NAD(P)H:quinone oxido-reductase) is required to activate 17DMAG by metabolizing its quinone moiety, and NQO1 downregulation is a predictive biomarker for resistance to this ansamycin class of Hsp90i 23, 24 . Indeed, we observed reduced NQO1 expression in escaper versus responder T-lymphomas ( Fig. 3g ). In sum, HSP90 inhibition prevented the development of T-lymphomas in mutp53 mice.
To reduce complexity and dosing of the combinatorial anti-HSP90 treatment, we eliminated HDAC inhibition and replaced 17DMAG with the highly potent synthetic Hsp90i ganetespib. Ganetespib has demonstrated a favourable safety profile in more than 1,200 cancer patients treated so far, and is currently being evaluated in 11 clinical trials including a phase 3 lung cancer trial (www.syntapharma. com) 25, 26 . On a molar basis, ganetespib is .50-fold more potent than 17AAG in degrading mutp53 and killing mutp53 cancer cells (Extended Data Fig. 4a -c). Moreover, ganetespib destabilized mutp53 but not wild-type p53 in human tumour cells and xenografts (Extended Data Fig. 4d-f ). Ganetespib also induced markedly more apoptosis in Q/2 versus p53-null T-lymphoma cells (Extended Data Fig. 4g , h). Likewise, ganetespib strongly suppressed tumour growth in allografts of Q/2 T-and B-lymphomas treated with prophylactic and therapeutic protocols (Fig. 4a, b and Extended Data Fig. 4i , j). Notably, this in vivo drug effect, marked by Hsp70 induction, correlated perfectly with mutp53 destabilization and induction of apoptosis within 24 h upon repeated dosing ( Fig. 4c, d ). Moreover, ganetespib synergized with conventional chemotherapy such as cyclophosphamide ( Fig. 4e and Extended Data Fig. 4k ).
Encouraged by these data, we performed long-term treatments of early disease (8 weeks) H/H and Q/2 ( Fig. 2f, 3b ) versus their respective p53 2/2 controls (note, they differ in genetic background 2,3,27,28 ) with one weekly dose of ganetespib (50 mg per kg) or vehicle lifelong. Strikingly, ganetespib benefited only mutp53 mice, representing a structural mutant (H allele) and a DNA-contact mutant (Q allele), but not p53-null mice, extending median overall survival of H/H mice from 157 to 233 days (48%, Fig. 4f ) and Q/2 mice from 146 to 232 days (59%, Fig. 4g ). Q/2 T-lymphoma-specific survival was also greatly extended ( Fig. 4h ). Importantly, clinically advanced autochthonous tumours in Q/2 mice responded to ganetespib with regression or Fig. 1c , endpoint 2) and mean fold changes at endpoint; n, number of allografts.
LETTER RESEARCH stagnation ( Fig. 4i ). H/H mice, whose lifespan is normally identical to p53-null mice 7 , responded to ganetespib with improved survival beyond p53-null controls (Fig. 4j ), whereas Q/2 mice, whose lifespan is significantly shorter than p53-nulls 2 (Extended Data Fig. 1d ), showed improved survival now resembling p53-nulls (Extended Data Fig. 4l ). The fact that ganetespib and genetic mutp53 removal (Extended Data Fig. 2d ) both cause floxQ/2 survival to overlap with p53-null mice supports the idea that ganetespib targets mutp53. However, ganetespib improved survival more efficiently than genetic mutp53 ablation (Extended Data Fig. 4m ), probably because of persistent destabilization of mutp53 compared with incomplete genetic ablation at 10 weeks.
Other tumour-promoting Hsp90 clients might also be inhibited by ganetespib, contributing to the difference. Overall, these data indicate that the effect of ganetespib is largely due to targeting mutp53, as it had no effect in p53-null mice ( Fig. 4f, g) . Moreover, consistent with superior potency of ganetespib versus 17DMAG1SAHA, weekly ganetespib monotherapy improved overall survival more efficiently than near-daily 17DMAG1SAHA therapy (Extended Data Fig. 4n ). Ganetespib treatment also correlated with absence of T-lymphomas in two of two Q/2 sibling pairs, while dimethylsulphoxide (DMSO)treated siblings exhibited large T-lymphomas ( Fig. 4k ). Finally, thymic tissues of Q/2 mice analysed at death again showed that when HSP90 inhibition was achieved (Hsp70 induced), mutp53 T-lymphomagenesis was prevented ( Fig. 4l ), while all five T-lymphomas that arose despite ganetespib again showed no evidence of drug activity (no Hsp70 induction) ( Fig. 4l , 5/23 (22%) escapers). In colorectal cancers we recently identified a major resistance mechanism for ganetespib (but not other classes of Hsp90i) via upregulation of the drug-conjugating enzyme UGT1A in tumour cells, causing drug efflux and tumour protection 29 . However, in mutp53 T-lymphomas, UGT1A (messenger RNA and protein) did not correlate with ganetespib resistance, necessitating future analysis to identify alternative mechanisms. Overall, these data indicate tumour dependence on high levels of mutp53 and demonstrate mutp53-dependent drug effects.
Missense mutp53 is highly expressed in 40-50% of all human tumours. One therapeutic strategy considered for nearly two decades is to develop small compounds capable of restoring the lost wild-type function of mutp53 proteins 30 . In the face of this daunting and still elusive goal, the results presented here show that eliminating stabilized mutp53 proteins can have positive therapeutic effects in vivo, even in the absence of wild-type p53, since such tumours show exploitable dependence on their gain-of-function. Targeting HSP90 represents the first and currently only viable clinical strategy to achieve this goal. 
METHODS
Generation of floxQ;ERT2 mice. The floxed HUPKI (humanized p53 knock-in) p53R248Q allele (referred to as floxQ) was generated by introducing loxP sites flanking exons 2-10 of the p53 locus where mouse exons 4-9 were replaced with human exons 4-9 containing a p53 R248Q mutation in exon 7, as described in Extended Data Fig. 1a -c. The p53 floxQ/1 mice were crossed with p53 2/2 mice on a 129SvImJ/C57Bl6J mixed background as previously described 2 to generate p53 floxQ/2 animals. The p53 floxQ/2 animals were then intercrossed with p53 Q/2 animals (previously described in ref.
2) to generate p53 floxQ/Q mice on a 129SvImJ/ C57Bl6J background. Rosa26 CreERT2/CreERT2 mice (referred to as ERT2) on a pure C57Bl6J background 31 were purchased from The Jackson Laboratory (stock 008463) and intercrossed with the mixed p53 2/2 animals to generate p53 2/2 ;Rosa26 ERT2/ERT2 mice. The p53 2/2 ;Rosa26 ERT2/ERT2 mice were intercrossed with p53 floxQ/Q or p53 2/2 to generate the p53 floxQ/2 ;Rosa26 ERT2/1 , p53 Q/2 ;Rosa26 ERT2/1 and p53 2/2 ;Rosa26 ERT2/1 cohorts. Mutant p53 (mutp53) knock-in mice for long-term drug studies. The p53 R172H/R172H mice (referred to as H/H) and their corresponding p53 2/2 controls on a pure C57Bl6J background were previously described 3, 27 . HUPKI p53 R248Q/2 mice (referred to as Q/2) and their corresponding p53 2/2 controls on a 129SvImJ/C57Bl6J mixed background were also previously described 2, 28 . Note that two different p53 2/2 control strains were used as corresponding genetic background-matching controls for H/H mice (pure C57BL/6J background) versus Q/2 mice (mixed 129SvImJ/C57Bl6J background). Mice were monitored twice a week and euthanized when animals appeared moribund or the largest palpable tumour reached 2 cm 3 or ulcerated. Males and females were used at 1:1 ratio (except for Nu/Nu mice, only males were used). According to Stony Brook University Institutional Animal Care and Use Committee (IACUC) guidelines and our approved protocol, the maximum tumour burden per mouse was 4 cm 3 , which was strictly followed in all experiments. Time of euthanasia was considered endpoint. All animals were treated humanely and according to the guidelines by the IACUC of Stony Brook University. Lymphoma cell isolation and allograft transplants. Primary T-lymphoma cells were isolated by mechanically mincing T-lymphoma tumours with a razor blade for 1 min, followed by 5 min incubation with 5 ml red blood cell lysis buffer at 22uC. Lymphoma medium (5 ml) (1:1 DMEM/IMDM supplemented with 10% FBS, L-glutamine, penicillin/streptomycin, antibiotic/antimycotic, b-mercaptoethanol; all from Gibco) was added and cells were passed through a 40 mm nylon cell strainer (Falcon) to remove cell clumps. Cells were spun down and resuspended in lymphoma medium. Primary B-lymphoma cells were isolated similarly, except for the addition of 100 ml of 3 M sodium acetate during mincing to prevent blood coagulation and a second round of red blood cell lysis buffer/lymphoma medium/spinning. Freshly isolated live B-and T-lymphoma cells were counted and either frozen or immediately used for in vitro studies or transplantations (allografts). For subcutaneous transplantation, 6-to 7-week-old Nu/Nu males (Harlan, strain Hsd:Athymic Nude-Foxn1 nu ) were injected into four dorsal sites with 10 5 lymphoma cells per site suspended in 3:1 PBS/Matrigel (BD Biosciences). For intravenous tail vein injections, 10 5 cells in PBS were injected per Nu/Nu recipient.
Removal of the conditional floxQ allele. To remove the floxQ allele in cells in vitro, T-lymphoma cells (15 3 10 6 live cells per 6 cm dish) grown in lymphoma medium were treated with 1 mM 4OHT (Sigma H7904) in EtOH for the times indicated in Extended Data Fig. 1e .
To remove the floxQ allele in T-lymphoma allografts, randomly assigned mice were injected intraperitoneally with 100 mg per kg or 150 mg per kg tamoxifen (Sigma T5648) in corn oil, or with corn oil alone, as indicated in Fig. 1 and Extended Data Fig. 1 . For the prophylactic protocol typically nine daily intraperitoneal injections beginning 2 days before lymphoma cell transplantation were given. For the therapeutic protocol five to seven daily intraperitoneal injections were given after at least two out of four palpable tumours had appeared.
For autochthonous tumours, to remove the floxQ allele in mice with early organ-confined disease, randomly assigned 10-week-old animals were injected intraperitoneal with 100 mg per kg tamoxifen in corn oil, or corn oil alone, daily for 5 consecutive days (Fig. 2f-h and Extended Data Fig. 2c-f ). As a pre-set criterion, animals that died from non-cancer-related causes (the minority) were excluded from subsequent analyses. To treat clinically advanced tumours ( Fig. 2a-e ), animals were monitored weekly by ultrasound imaging using the Visual Sonics Vevo 770 High-Resolution Imaging System. When tumours had reached 150 mm 3 on average (ranging from 86 to 218 mm 3 ), mice were injected with 150 mg per kg tamoxifen daily for 7 days, followed by 100 mg per kg three times a week, or with oil, until they needed to be killed (endpoint). To follow the response in vivo, tumours were imaged weekly by ultrasound and tumour volume was calculated using Vevo 770 V3.0.0 software.
Hsp90 inhibitor studies. HSP90 is crucial for cancer cell survival 32 . Cultured cells were treated with 2.5 mM or 5 mM 17-allylamino-17-demethoxygeldanamycin (17AAG, LC Laboratories, A-6880) or 5-500 nM ganetespib in DMSO for 24 h or 48 h. For xenografts, human cancer cells were subcutaneously injected into nude mice (0.5 Mio cells per site in 100 ml Matrigel, four sites per mouse). Tumours became visible around day 10. For Fig. 3a and Extended Data Fig. 3 , treatment of 10 mg per kg 17AAG and/or 25 mg per kg SAHA (vorinostat/suberoylanilide hydroxamic acid, LC Laboratories, V-8477) in DMSO or vehicle control was started at day 24 every other day, with endpoint at day 44 or earlier in the few cases where tumours became ulcerated.
For 17DMAG1SAHA treatments of H/H and corresponding p53 2/2 mice, 17DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin, LC Laboratories D-3440), a hydrophilic derivative of 17AAG 33 , was dissolved in 5% (w/v) hydroxypropyl-b-cyclodextrin (HOP-b-CD) (Sigma 332607), and SAHA (LC Laboratories V-8477) was dissolved in a 5 M equivalent of HOP-b-CD as previously described 34 . Equal volumes of 17DMAG and SAHA (or both vehicle solutions) were combined and frozen in aliquots until use. Starting at 8 weeks of age, randomly assigned animals received 100 ml intraperitoneal injections of 10 mg per kg 17DMAG plus 25 mg per kg SAHA, or 100 ml HOP-b-CD vehicle, for 5 days a week until endpoint (death). As a pre-set criterion, animals that died from non-cancer-related causes (the minority) were excluded from subsequent analyses.
For ganetespib treatments of H/H and Q/2 mice and their corresponding p53 2/2 control cohorts, ganetespib (aka STA-9090, Synta Pharmaceuticals) was dissolved in 10% DMSO/18% cremophor/3.6% dextrose ('10/18 DRD') as previously described 35 . For reference, rodents safely tolerate doses of ganetespib of up to 150 mg per kg once weekly or 75 mg per kg twice weekly 36 . Randomly assigned animals received freshly prepared ganetespib or the corresponding volume of 10/ 18 DRD vehicle by tail vein injection as follows: 50 mg per kg ganetespib once a week starting at 8 weeks of age until death for the treatment of autochthonous tumours (including the sibling analysis in Fig. 4j ); 75 mg per kg ganetespib twice a week for the treatment of T-and B-lymphoma allografts (beginning 1 day before lymphoma transplantation in the prophylactic protocol, or beginning when at least two out of four palpable tumours per mouse had appeared in the therapeutic protocol); 150 mg per kg of ganetespib once or twice for acute high-dose treatment (Fig. 4c, d) . As a pre-set criterion, animals that died from non-cancer-related causes (the minority) were excluded from subsequent analyses. For the sibling analysis (Fig. 4j) , the sisters were killed at 90 days and the brothers at 148 days, each 24 h after their last treatment, and their thymic tissues were subjected to immunoblot analysis. Cyclophosphamide was dissolved in PBS and injected intraperitoneal at indicated doses. Human cancer cell lines. Breast cancer MDA231 (p53R280K, HTB-26), MDA468 (p53R273K, HTB-132), T47D (p53L194F, HTB-133), SKBR3 (p53R175H, HTB-30), prostate cancer DU145 (p53P223L and p53V274F, HTB-81), non-small-cell lung cancer H1975 (p53R273H, CRL-5908) and ovarian cancer cell line ES2 (p53S241F, CRL-1978) were purchased from the American Type Culture Collection. The ovarian cancer lines EFO21 (p53C124R, ACC-235) and COLO704 (p53wt, ACC-198) were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen. The ovarian cancer cell line COV434 (p53wt) was purchased from Sigma-Aldrich (07071909). The ovarian cancer cell line HOC7 (p53C275F) was a gift from N. Concin. Paired parental MDA231 and MDA2311R280K cells stably overexpressing pcDNA3 vector or pcDNA3-p53R280K plasmids, respectively, were generated by transfection and selection. All cells were cultured in DMEM/10% FCS and tested negative for mycoplasma. No further authentication of cell lines was performed. Cell death. Cell death was determined by CellTiter-Blue Cell Viability Assay (Promega G808A) according to the manufacturer's instructions, in six-well plate format with five Mio lymphoma cells per well or 150,000 human cancer cells per well. Cells were treated as indicated and fluorescence was detected by FILTERmax F5 (Molecular Devices). Trypan Blue exclusion assays were done by direct manual counting of transparent (live) cells in a haemocytometer and normalizing counts to vehicle control. Immunohistochemistry and immunoblot analysis. For immunohistochemical analysis, tumours were fixed in formalin, embedded in paraffin and sectioned (5 mm). Slides were deparaffinized and boiled in citrate buffer (10 mM, pH 6.0, 35 min) for antigen retrieval, blocked in 10% goat serum and incubated with primary antibodies (mutp53, Santa Cruz FL393, sc-6243, 1:500; cleaved caspase 3, Cell Signaling 9661, 1:500; phosphor-S28 histone H3, Abcam ab32388, 1:300) for 2 h at room temperature. After PBS washing, slides were incubated with biotinylated secondary antibody and HRP-streptavidin using the Histostain SP Broad Spectrum kit (Invitrogen 959943B), stained with DAB substrate with haematoxylin counterstain and coverslipped. Immunoblots were performed using 20 mg of total protein extract from tumours or tumour cells with the following LETTER RESEARCH Extended Data Figure 4 | Ganetespib kills mutp53 human and mouse cells in a mutp53-dependent manner. a-c, On a molar basis, ganetespib is .50-fold more potent than 17AAG in degrading mutp53 and killing human mutp53 cancer cells. MDA468 (p53R280K) (a) and T47D (p53L194F) (c) breast cancer cells, as well as ES2 (p53S241F) ovarian cancer cells (b), were seeded into six-well plates and treated for 24-48 h. After incubation, dead cells were washed off and total protein lysates from only live cells were immunoblotted as indicated. CTB assays on parallel cultures for cell viability show drug activity. c, SKBR3, (p53R175H) breast cancer cells; DU145, heterozygous (p53P223L/V274F) prostate cancer cells. Mean 6 s.e.m. of four (b) or three (c) technical replicas, unpaired two-tailed Student's t-test. p-Akt and p-Erk are also Hsp90 clients; cleaved PARP indicates activated apoptosis. d-f, Ganetespib destabilizes mutp53 but not wtp53 in cultured human ovarian carcinoma cells EFO21 (p53C124R) and HOC7 (p53C275F) (d), wtp53 COV434 and COLO704 (e) and in human non-small-cell lung cancer xenografts H1975 (p53R273H) (f). Nude mice bearing tumour xenografts (each lane is an independent tumour) were treated with a single bolus of DMSO or ganetespib (50 mg per kg intravenously), tumours were harvested at baseline (30 min), 48 h and 72 h and cells were lysed and immunoblotted as indicated (f). Chk1 and CDK1 are other Hsp90 clients; cleaved PARP indicates activated apoptosis. g, h, Ganetespib decreases stabilized mutp53 levels in live Q/2 T-lymphoma cells within 24 h, associated with induction of apoptosis. Freshly isolated live Q/2 T-lymphoma cells were treated with DMSO or 50 nM ganetespib for 24 h, followed by immunoblots as indicated, Hsp70 indicates drug activity, Hsc70 is the loading control (g), Death curves of freshly isolated Q/2 and p53 2/2 T-lymphoma cells treated with DMSO or 50 nM ganetespib for the indicated times, CTB and trypan blue exclusion assays (h). All values are relative to DMSO treatment at the same time point. Mean 6 s.e.m., unpaired two-tailed Student's t-test, n 5 4 independent isolates per genotype for every time point, *P , 0.05, **P , 0.01. i, j, Ganetespib suppresses growth of subcutaneous allografts of Q/2 B-lymphoma. Prophylactic protocol; treatment days are indicated in red, tumour cell injection is marked by arrow, time course of allograft growth; n, number of allografts (i), Therapeutic protocol (same as in Fig. 4b ) and tumour mass at endpoint (j). Mean 6 s.e.m.; unpaired two-tailed Student's t-test; n, number of allografts. k, Ganetespib yields synergistic antitumour effects in combination with cyclophosphamide. Subcutaneous allografts of Q/2 and H/H T-lymphoma cells were treated once (arrow) with the indicated doses of ganetespib or cyclophosphamide alone or in combination. The mean 6 s.e.m. allograft size for Q/2 and H/H at the start of treatment was 274 6 36 mm 3 and 323 6 44 mm 3 , respectively. Unpaired twotailed Student's t-test; n, number of allografts. Each single drug is compared with the combination. *P , 0.05, **P , 0.01. l, Comparison of ganetespib treatment of floxQ/2 versus corresponding p53 2/2 control mice from Fig. 4g . The floxQ/2 mice, which normally have a significantly shorter lifespan than p53-null littermates 2 (median 139 days versus 195 days, respectively, see also Extended Data Fig. 1d ) respond to ganetespib with significantly longer survival (right shift) and now resemble that of p53 2/2 mice. Kaplan-Meier analysis, log rank statistics. m, n, Ganetespib monotherapy once a week improves overall survival more efficiently than either genetic mutp53 ablation or 17DMAG1SAHA given five times a week. Comparison of Kaplan-Meier survival curves (log rank statistics) of tamoxifen-treated floxQ/2 animals from Fig. 2g and ganetespib-treated floxQ/2 animals from Fig. 4g (m) . Note, on the basis of their phenotypic identity (see Extended Data Fig. 1d ), floxQ/2 mice were used in Fig. 4g in lieu of Q/2 to ensure direct comparability with tamoxifen treatment. Comparison of Kaplan-Meier survival curves (log rank statistics) of 17DMAG1SAHA-treated H/H animals from Fig. 3c and ganetespib-treated H/H animals from Fig. 4f (n). In this Letter on page 353, the words 'substrate Hsp90' should have been included in this sentence as follows: "Likewise, histone deacetylase inhibitors, including FDA-approved SAHA, are promising anticancer drugs whose actions involve hyperacetylation of histone and select non-histone targets including HDAC6 substrate Hsp90, thus indirectly inhibiting Hsp90 (ref. 21) ". This has been corrected in the online versions.
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